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Probiotics improve 
the neurometabolic profile of rats 
with chronic cholestatic liver 
disease
Veronika Rackayová1,9, Emmanuelle Flatt1, Olivier Braissant2, Jocelyn Grosse3, 
Daniela Capobianco4, Paola Mastromarino4, Matthew McMillin5,6, Sharon DeMorrow5,6,7, 
Valérie A. McLin8 & Cristina Cudalbu9*
Chronic liver disease leads to neuropsychiatric complications called hepatic encephalopathy (HE). 
Current treatments have some limitations in their efficacy and tolerability, emphasizing the need for 
alternative therapies. Modulation of gut bacterial flora using probiotics is emerging as a therapeutic 
alternative. However, knowledge about how probiotics influence brain metabolite changes during 
HE is missing. In the present study, we combined the advantages of ultra-high field in vivo 1H MRS 
with behavioural tests to analyse whether a long-term treatment with a multistrain probiotic mixture 
(VIVOMIXX) in a rat model of type C HE had a positive effect on behaviour and neurometabolic 
changes. We showed that the prophylactic administration of this probiotic formulation led to an 
increase in gut Bifidobacteria and attenuated changes in locomotor activity and neurometabolic 
profile in a rat model of type C HE. Both the performance in behavioural tests and the neurometabolic 
profile of BDL + probiotic rats were improved compared to the BDL group at week 8 post-BDL. They 
displayed a significantly lesser increase in brain Gln, a milder decrease in brain mIns and a smaller 
decrease in neurotransmitter Glu than untreated animals. The clinical implications of these findings 
are potentially far-reaching given that probiotics are generally safe and well-tolerated by patients.
Chronic liver disease (CLD) is often accompanied by type C hepatic encephalopathy (HE) which becomes appar-
ent as liver disease progresses or as patients experience precipitating factors.
Ammonium is known to play a central role in the pathogenesis of  HE1. The main source of systemic ammo-
nium is believed to be the gut, partially from urea breakdown by urease producing colonic bacteria and glu-
tamine deamidation by  glutaminase2,3. In cirrhotic patients, it has been shown that urease producing bacteria 
are  increased4,5 leading to increased urea breakdown and ammonia  absorption6.
There is increasing evidence that chronic liver disease is accompanied by qualitative and quantitative changes 
in the intestinal flora. Changes in gut microbiota in CLD include a decrease in autochthonous and an increase in 
potentially pathogenic bacteria, which become more pronounced with progression of liver  disease7–9. Dysbiosis 
and bacterial overgrowth both of which are present in cirrhotic  patients9–11 can lead to increased production of 
 endotoxins8,12–14 entering the  circulation15. Furthermore, dysbiosis and secondary intestinal  inflammation16–18 
may lead to increased gut permeability, in turn leading to bacterial  translocation19,20. Together, this increases 
systemic  inflammation8,21 and further contributes to the progression of liver disease and its complications. It is 
recognized that modifications in gut flora are implicated in the complications of liver cirrhosis or CLD, including 
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spontaneous bacterial peritonitis (SBP) and other  infections22,23, all of which are considered precipitating fac-
tors of HE.
Non-absorbable disaccharides (e.g. lactulose or lactitol) or non-absorbable antibiotics such as rifaximin are 
the most commonly used therapies in HE. The mechanisms of action of these treatments are not yet fully under-
stood, but the main effect is probably linked to changes in gut bacterial metabolic functions and microbiome 
composition (mainly through decrease ammonia production in the gut and its absorption)24,25. However, these 
treatments have some limitations in their efficacy and tolerability, emphasizing the need for alternative therapies. 
Modulation of gut bacterial flora using probiotics is emerging as a therapeutic alternative. Not only may they 
present additional benefits, but they are also generally well tolerated  clinically26,27.
If the right strains of probiotic bacteria are used, a decrease of pathogenic bacteria will lead to decreased pro-
duction of gut-derived bacterial  toxins28 and  ammonium29–31 and also help restore intestinal barrier  integrity32. 
A probiotic formulation consisting of a mixture of eight strains (VIVOMIXX in EU, VISBIOME in USA) has 
been associated with significant improvement in minimal HE (mHE) symptoms in  humans33, decreasing hospi-
talization rates and preventing HE episodes in patients with  cirrhosis34. It has also been shown recently that this 
probiotic formulation improved cognitive function and inflammatory response in patients with  cirrhosis35. In 
general, the effect of probiotics was similar to  lactulose36–38 but with an improved tolerability profile. It should be 
noted that there was a wide variability in type of strain, daily dose and length of treatment in most of previously 
published studies, limiting the interpretation of treatment efficacy.
Type C HE is associated with neurometabolic changes in patients. These are characterized by an increase in 
brain glutamine (measured as the sum of glutamine and glutamate at low magnetic fields) due to ammonium 
detoxification, and consequent decrease of other brain metabolites, such as myo-inositol or choline-containing 
 compounds39,40. It was also shown that these changes may underlie neuropsychiatric  impairment41.
In animal models of type C HE, more detailed neurometabolic changes have been measured using longitu-
dinal in vivo 1H MRS or a combination of 1H MRS and 31P MRS at ultra-high field (9.4 T), including changes in 
antioxidant, neurotransmitter and energy  metabolites39,42,43. Yet, the studies evaluating the effects of probiotics 
are sparse in type C HE animal models. D’Mello et al. reported that probiotics (formulation sold as VSL#3 until 
2016, but now exclusively available under the brands VIVOMIXX and VISBIOME) improved inflammation-
associated sickness behaviour in a mouse model of liver  inflammation44. One study reported reduced liver 
fibrosis and hepatic gene expression of Interleukin-6 (IL-6) in BDL rats when using the probiotic Lactobacillus 
rhamnosus  GG45.
To date, the efficacy of probiotics on HE has mainly been assessed using neurological  testing46. Knowledge 
about how probiotics influence brain metabolite changes, commonly present during HE, is missing. Therefore, 
our study aimed to use the advantages of ultra-high field in vivo 1H MRS combined with behavioural tests to 
analyse whether a long-term treatment with a multistrain probiotic mixture (VIVOMIXX) in a rat model of 
type C HE attenuated the behavioural and neurometabolic changes typically observed in this model. We focused 
specifically on brain metabolites (i.e. glutamine and glutamate separately, taurine, creatine, γ-aminobutyric 
acid, phosphocreatine, ascorbate or glutathione) involved in osmoregulation, neurotransmission, energy or 
antioxidant metabolism.
Methods
Adult male Wistar rats (Charles River laboratories, L’Arbresle, France, 160–195 g) underwent bile duct ligation 
(BDL) or sham operation to reproduce an accepted model of type C  HE47. Animals were kept in the animal facility 
with 12 h/12 h light/dark cycle. Standard rat chow and water was available ad libitum for the duration of study. 
All animal experiments were conducted according to federal and local ethical guidelines, and the protocols were 
approved by the local Committee on Animal Experimentation for the Canton de Vaud (Switzerland).
Study design. In the present study, thirty-eight rats were separated into 4 groups: 14 BDL rats with pro-
biotic administration (BDL + probiotic), 14 BDL rats without treatment (BDL), 5 sham operated animals with 
probiotic administration (sham + probiotic) and 5 sham operated animals without treatment (sham). Of note, 
the “BDL” rats and the measures performed using these rats are part of a previously published  study43.
Daily probiotic administration started 2 weeks before BDL or sham surgery and lasted until the end of the 
study (8 weeks post-BDL). The dose of 60 billion probiotic bacteria/kgrat/day was dissolved in saline solution 
and given by voluntary drinking from a syringe (without needle). The group without treatment received the 
same volume of saline solution. As a probiotic mixture we used VIVOMIXX (Mendes S.A., Lugano, Switzerland) 
containing 8 lyophilized, highly viable bacterial strains: 4 lactobacilli (Lactobacillus acidophilus DSM24735, L. 
plantarum DSM24730, L. paracasei DSM24733, L. bulgaricus DSM24734), 3 Bifidobacteria (Bifidobacterium 
infantis DSM24737, B. longum DSM24736, B. breve DSM24732) and Streptococcus thermophilus DSM24731).
The longitudinal study design with the timing of various sample collections or measurements is illustrated 
in Table 1 During the MR experiments and blood sampling (from the sublingual vein at the beginning of the 
afternoon), animals were kept under 1.5–2% isoflurane anaesthesia (in a mixture of 50% air and 50% oxygen) 
with respiration rate maintained at 60–70 breaths/min and body temperature at 37.5–38.5 °C.
Gut microbiota analysis. Faeces were collected at weeks 0, 4 and 8 to measure Bifidobacteria concentra-
tion. Measurements were performed as described  previously48.
Plasma analysis. Plasma samples were analysed using REFLOTRON System for glucose, INTEGRA 400 
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1H MRS. Measurements were conducted on a horizontal actively shielded 9.4 T system (Magnex Scientific, 
Oxford, UK) interfaced to a Varian Direct Drive console (Palo Alto, CA, USA) as previously  described43. 1H 
localized spectra were acquired with the ultra-short echo-time  SPECIAL43,49 spectroscopy sequence (TE = 2.8 
ms, TR = 4 s, 160 averages) in a volume of interest (VOI = 2 × 2.8 × 2  mm3) placed in the dorsal hippocampus. 
Hippocampus, as a part of the limbic system, was chosen for 1H MRS measurements due to known problems 
with learning and memory in HE  patients50.
Spectra were fitted and metabolite concentrations were calculated by LCModel and expressed in mmol/kgww 
using the unsuppressed water signal from the same VOI as an internal reference, assuming 80% water in the 
tissue, as previously  described43. The Cramer–Rao lower bounds (CRLB) were used as a reliability measure for 
the metabolite concentration estimate. Only metabolites with CRLB lower than 30% were considered for further 
analysis. The ultra-short echo-time MRS allowed the detection of the following 18 metabolites, all included in 
basis-set: alanine (Ala), ascorbate (Asc), aspartate (Asp), glycerophosphocholine (GPC), phosphocholine (PCho), 
creatine (Cr), phosphocreatine (PCr), γ-aminobutyric acid (GABA), glucose (Glc), glutamine (Gln), glutamate 
(Glu), glutathione (GSH), myo-inositol (mIns), lactate (Lac), N-acetylaspartate (NAA), N-acetylaspartylgluta-
mate (NAAG), phosphoethanolamine (PE) and taurine (Tau).
Changes of brain metabolites over time were expressed in absolute values (mmol/kgww) and also as % changes. 
Our non-invasive method allows us to scan the animals before BDL and to follow the same animals longitudinally. 
Thus, the metabolic changes in the brain during the progression of disease could be compared to the pre-BDL 
scan and expressed as % changes in each animal for all the other time-points.
Behavioural tests—open field test. Locomotor activity was assessed in the open field (OF) test as previ-
ously  described43.
Statistical analysis. All results are presented as mean ± SEM. One-way ANOVA (Prism 5.03, Graphpad, 
La Jolla CA USA) with the Bonferroni’s multi-comparisons post-test (weeks post-BDL, 6 comparisons) were 
used to assess significance in each brain and plasma metabolite’s, Bifidobacteria and behavioural measurement 
within a single group (*p < 0.05; **p < 0.01; ***p < 0.001). Gut microbiota analyses were performed on data in log-
arithmic scale. Two-way ANOVA (Prism 5.03, Graphpad, La Jolla CA USA) followed by the Bonferroni’s multi 
comparisons post-test was used to assess significance (p < 0.05) of changes in each brain metabolite between the 
groups (with weeks post-BDL and groups as factors). However, given the difficulty of interpreting the p values of 
two-way ANOVA when interaction is significant (treated rats showing changes different from BDL rats in some 
measurements, as expected), one-way ANOVA was also used to evaluate differences between BDL non-treated 
and BDL + probiotic in a given week. P values are shown in tables and figures only.
Results
Gut microbiota: Bifidobacteria increase in BDL + probiotic rats. Gut microbiota (Fig. 1) showed 
a significant increase of the amount of Bifidobacteria between week -2 (beginning of probiotic treatment) and 
week 6 in BDL + probiotic and a trend toward an increase in sham + probiotic. At week 6, both BDL + probiotic 
and sham + probiotic showed a significantly higher level of Bifidobacteria as compared to BDL or sham, respec-
tively. No significant change was observed in BDL rats throughout the study.
Plasma measurements and body weight: differences between shams and BDL rats. Plasma 
bilirubin, a marker of liver disease, was undetectable (< 0.5 mg/dl) in all animals before surgery and stayed unde-
tectable in shams (with or without probiotic) throughout the study. In both BDL and BDL + probiotic groups, 
Table 1.  Longitudinal study design. The number of rats (n) measured in every group are indicated for each 
week and each type of measures: ‘MRS’ stands for MRS scan, ‘B’ for the rats whose Bifidobacteria in the faeces 
were analysed, and ‘O-F’ for the rats who undergone open field test. Of note, for blood sampling we used 
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plasma bilirubin increased already 2 weeks post-BDL and continued to increase until week 8 without significant 
difference between the two groups (Table 2). Plasma NH4+ was in the normal range before surgery in all animals 
and stayed normal in shams, with no difference between shams and shams + probiotic over the course of the 
study (Table 2). Plasma  NH4+ at week 6 and 8 was slightly lower in the BDL + probiotic group when compared to 
the BDL group, although this did not reach statistical significance. Plasma glucose was in the same range before 
the surgery in all animals and remained in the normal range in both in shams and shams + probiotic throughout 
the study. In BDL and BDL + probiotic rats plasma glucose levels decreased progressively over the course of the 
disease (Table 2). Even though BDL and BDL + probiotic had lower body weight than shams and shams + probi-
otic, the difference did not reach statistical significance. At week 8, mean body weights were: 299 ± 10 g in BDL 
group, 336 ± 16 g in BDL + probiotic group, 352 ± 17 g in sham group and 363 ± 13 g in sham + probiotic group.
1H MRS: BDL + probiotic rats display an attenuated rise in brain Gln. The spectral quality with vis-
ible increase in brain Gln in BDL rats is shown on Fig. 2. Brain Gln increased in both BDL and BDL + probiotic 
rats, but the BDL + probiotic group displayed a significantly slower and attenuated increase (Fig. 3A,B). BDL 
rats showed a significant + 61 ± 13% increase of Gln already 4 weeks post-BDL, reaching + 171 ± 22% at week 8. 
In BDL + probiotic the rise in Gln occurred later, becoming significant only at 6 weeks post-BDL and reaching 
only + 114 ± 38% increase at week 8.
Figure 1.  Amount of Bifidobacteria/g of faeces expressed in normal and logarithmic scale. One-way ANOVA 
was used for statistical analysis, shown on the logarithmic scale graph: *between sham and sham + probiotics at 
week 6, ▪between BDL and BDL + probiotic at week 6, + between BDL + probiotic between week − 2 and week 6.
Table 2.  Evolution of plasma glucose,  NH4+ and bilirubin in BDL, BDL + probiotic, sham and sham + probiotic 
animals during disease progression. Plasma  NH4+ showed no difference between shams and shams + probiotic. 
Therefore, we pooled them together for the analysis. P value: for plasma glucose and plasma  NH4+, one-way 
ANOVA with Bonferroni correction, *significance between BDL and sham groups, +significance between 
BDL + probiotic and sham groups. ns non-significant. For plasma bilirubin, one-way ANOVA with Bonferroni 
correction statistics are shown between BDL and BDL + probiotic.
BDL BDL + probiotic Sham Sham + probiotic p value
Plasma glucose (mg/dl)
Week 0 189 ± 6 193 ± 6 176 ± 19 192 ± 3 ns
Week 2 148 ± 11 154 ± 4 158 ± 4 171 ± 5 ns
Week 4 140 ± 5 134 ± 7 161 ± 4 169 ± 10 +
Week 6 111 ± 5 97 ± 8 156 ± 11 187 ± 24 *,+++
Week 8 92 ± 8 117 ± 7 200 ± 7 153 ± 11 ***
Plasma NH4+ (μM)
Week 0 61.2 ± 3.5 68.2 ± 8.5 68.9 ± 8.9 ns
Week 2 80.4 ± 5.5 93 ± 5.9 69.5 ± 11.3 ns
Week 4 106 ± 9.2 103.7 ± 10.9 50.9 ± 0.6 *
Week 6 126.4 ± 10.1 103.0 ± 8.1 60.6 ± 3.6 *
Week 8 152.9 ± 26.0 124.6 ± 17.1 53.9 ± 2.8 **,+
Plasma bilirubin (mg/dl)
Week 0 < 0.5 < 0.5 < 0.5 < 0.5 ns
Week 2 4.7 ± 0.2 5.8 ± 0.5 < 0.5 < 0.5 ns
Week 4 6.2 ± 0.3 6.6 ± 0.3 < 0.5 < 0.5 ns
Week 6 6.9 ± 0.5 7.1 ± 0.4 < 0.5 < 0.5 ns
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Gln increase was followed by mIns decrease in both BDL and BDL + probiotic groups. In BDL rats, mIns 
decreased significantly by − 34 ± 4% at 8 weeks post-BDL (Fig. 3C,D). The decrease in BDL + probiotic was less 
pronounced (− 24 ± 8%), which was expected since Gln increase was lesser in BDL + probiotic, given that a mIns 
decrease is generally considered as an osmoregulatory response to Gln increase.
Among the other brain organic osmolytes, tCho and Tau decreased in both BDL and BDL + probiotic, and 
there was no significant difference in their decrease between BDL and BDL + probiotic group at 8 weeks post-BDL 
(Table 3). tCho decreased by − 13 ± 11% at 8 weeks post-BDL in BDL group and by − 22 ± 8% in BDL + probiotic. 
Tau decreased by − 7 ± 2% in BDL group and − 13 ± 2% in BDL + probiotic at 8 weeks post-BDL.
The neurotransmitter Glu decreased in both BDL and BDL + probiotic groups, but the decrease was slightly 
less pronounced in BDL + probiotic rats (− 10 ± 3.4% in BDL + probiotic vs − 12 ± 1.9% in BDL rats at 8 weeks 
Figure 2.  Representative in vivo 1H MRS spectra 8 weeks after surgery from sham rat, sham + probiotic rat, 
BDL rat and BDL + probiotic rat (SPECIAL sequence, TE = 2.8 ms, TR = 4000 ms, 160 averages). Blue bands 
highlight glutamine resonance that is visibly increased in BDL rats with smaller increase in BDL + probiotic rat. 
 T2 weighted axial image of the rat brain indicates position of measured volume (2 × 2.8 × 2mm3) placed in dorsal 
hippocampus. Ala alanine, Asc ascorbate, Asp aspartate, GPC glycerophosphocholine, PCho phosphocholine, 
Cr creatine, PCr phosphocreatine, GABA γ-aminobutyric acid, Glc glucose, Gln glutamine, Glu glutamate, 




Scientific Reports |         (2021) 11:2269  | https://doi.org/10.1038/s41598-021-81871-8
www.nature.com/scientificreports/
Figure 3.  Longitudinal brain Gln, mIns and Glu. Expressed in absolute concentration as mmol/kgww (mmol 
per kg wet weight) (A,C,E) and % changes as compared to scan 0 (B,D,F). Significance (one-way ANOVA with 
Bonferroni corrections) on graphs (A,C,E) in comparison to brain concentration of corresponding metabolite at 
week 0 (black, red) or between the two groups for a given week (grey). ns non-significant.
Table 3.  Concentration changes of some brain metabolites 8 weeks after BDL surgery in BDL and 
BDL + probiotic groups. 1 One-way ANOVA repeated measure between concentrations of corresponding 
metabolite at week 0 and week 8 after BDL surgery. 2 One-way ANOVA between % changes of corresponding 
metabolite in BDL and BDL + probiotic groups.
Brain metabolite
Concentration changes 8 weeks after BDL
BDL vs BDL + probioticBDL BDL + probiotic
Mean (%) SEM (%) p  value1 mean (%) SEM (%) p  value1 p  value2
tCho − 13 11 ns − 22 8 0.04 ns
Tau − 7 2 0.005 − 13 2 0.0004 ns
Cr − 7 3 0.05 − 12 4 0.05 ns
PCr − 12 4 0.01 − 15 3 0.002 ns
tCr − 10 1 0.0001 − 14 3 0.002 ns
Asc − 12 8 ns − 18 8 0.05 ns
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post-BDL) (Fig. 3E,F). The decrease in other brain metabolites (Cr, PCr, tCr, Asc) was not significantly differ-
ent between BDL and BDL + probiotic groups and their evolution at 8 weeks post-BDL is shown in Table 3. In 
addition, no significant changes were observed in Ala, Asp, GABA, GSH, PE, NAA, NAAG nor tNAA during 
the progression of disease neither in BDL or BDL + probiotic group. Finally, there was no significant differences 
observed between shams and sham + probiotic group for any given metabolite (data not shown).
Behavioural tests: better performance in BDL + probiotic rats. BDL + probiotic group also exhib-
ited a better performance in the Open Field test compared to BDL group (Fig. 4). Eight weeks post-BDL, the 
BDL group walked 38.8 ± 5.3 m less that their shams during the 10 min Open Field test. On the other hand, 
BDL + probiotic rats displayed stable performance between weeks 4, 6 and 8 post-BDL compared to shams, 
walking only 7.3 ± 6.5 m less that the shams at week 8. This difference at week 8 was significant between BDL 
and BDL + probiotic group. There were no differences for the following: time spent in the wall-zone, centre-zone 
and inter-zone, and latency to enter centre zone, suggesting animal anxiety was not a variable (data not shown).
Discussion
In the present study, we showed that prolonged administration of a multistrain probiotics mixture (VIVOMIXX) 
in a rat model of type C HE resulted in a milder course of HE compared to untreated animals. The administration 
of probiotics reduced plasma ammonium in BDL rats and was associated with milder changes in the neuro-
metabolic profile compared to BDL rats without probiotics. Both the neurometabolic profile of BDL + probiotic 
rats and their performance in behavioral tests were improved at week 8 post-BDL compared to the BDL group 
without treatment.
A lower plasma ammonium concentration was observed in BDL + probiotic group, possibly related to the 
modification of gut flora by the probiotic bacteria. The probiotic mixture used in our study led to an increase 
in Bifidobacteria in the gut of treated rats, both in shams and BDL, as shown in Fig. 1. This probably reflects the 
ability of probiotics to alter the microbiota composition in the gut. In BDL rats, such an alteration can decrease 
urea-derived production and absorption of ammonium, in agreement with previous studies where decreased 
ammonium has been linked to probiotics  utilization29–31. Furthermore, probiotics may also reduce plasma ammo-
nium by decreasing intestinal permeability, improving the gut epithelial integrity or increasing the ability of the 
liver to detoxify  ammonium32. It has been shown that the autochthonous taxa of gut bacteria can reduce endotox-
emia, intestinal inflammation, and nourish colonocytes by producing short-chain fatty acids and maintain good 
intestinal  barrier32,51. Moreover, probiotic supplementation was also shown to decrease systemic  inflammation52 
and production of gut-derived bacterial  toxins28, and to reduce risk of hospitalization of cirrhotic  patients53.
As previously mentioned, the efficacy of probiotics on HE has been mainly assessed through neurological 
testing. Some studies have shown that probiotics are effective in improving minimal symptoms or progression to 
overt HE as compared to  placebo27,36,54,55. In the present study, a significantly better performance in behavioural 
tests was observed in BDL + probiotic group compared to the BDL group without treatment, which coincided 
with attenuated neurometabolic changes compared to untreated animals. In particular, the brain Gln was lesser 
with a consequently milder mIns response.
Gln is probably the first metabolite influenced by increased plasma  ammonium43, and both are considered 
responsible for many of the changes in HE. Also, it is commonly accepted in chronic HE that increased plasma 
ammonium generates a rise in the brain osmolyte Gln leading to osmotic imbalance followed secondarily by a 
partial compensation through the gradual decrease of other brain  osmolytes43,56. The observed effect of probi-
otic treatment in our study could be attributed to lower plasma levels of ammonium with consequently lower 
Figure 4.  Performance in open field test. In black, difference in distance moved in meters (m) during the open 
field test between BDL rats and their shams at corresponding weeks. In red, difference between BDL + probiotic 
rats and their shams (sham + probiotic). There was no significant change between any weeks in BDL + probiotic 
group. Significance (one-way ANOVA with Bonferroni corrections) is given intra-group (black, red) or between 
the two groups at week 8 (grey).
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brain Gln and mIns concentrations. Of course, the effect on both gut- and systemic inflammation may also have 
contributed, something warranting further studies.
We also measured a smaller decrease in the neurotransmitter Glu in the BDL + probiotic group compared to 
the untreated BDL rats. It is now well known that HE is linked to disturbances in the neurotransmission systems 
(including glutamatergic among others) although their direct role is still not fully  understood57. This smaller Glu 
decrease may also have been secondary to the attenuated Gln increase in the treated rats, given that Gln synthesis 
is connected with Glu through the glutamate-glutamine cycle. Moreover, our previous studies have shown that 
the reduction in the cytosolic pool of Glu in BDL rats could simply be the result of ammonium detoxification 
driven by increased Gln synthesis from Glu in astrocytes without consequences on  neurotransmission58.
The present study has some limitations. We focused on the assessment of brain metabolites changes in BDL 
rats receiving VIVOMIXX. As such, no experiments assessing systemic or central inflammation were performed, 
something which would need further investigation in future studies. In addition, the increase in Bifidobacteria in 
the gut of both shams and BDL-treated rats observed in our study needs further investigation since the number 
of samples for gut microbiota measurements were limited.
In conclusion, the administration of a specific probiotic formulation (VIVOMIXX) in a prophylactic manner 
(treatment started before the beginning of the disease) had a beneficial effect on the development of HE in a rat 
model of type C HE, both when analysing locomotor activity and neurometabolic profile. It reduced or delayed 
disease progression, probably by decreasing plasma ammonium which may be related to increasing Bifidobacteria 
in the gut and slowing down the occurrence of precipitating factors. These are positive findings as some of these 
metabolic changes in the brain reflect disease  severity41. Recently, it was shown that MRS changes (Glx, Ins, tCho) 
in cirrhotic patients were correlated to changes in gut  microbiota11. Taken together, these results are promising 
and warrant further investigation. The clinical implications of these findings are potentially far-reaching given 
that probiotics are generally safe and well-tolerated by  patients26,59,60 in contrast to  lactulose61,62.
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